Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59 |
Hong, Jeong-Won
(Department of Pathology, Chungbuk National University College of Medicine)
Cho, Woon-Dong (Department of Pathology, Chungbuk National University College of Medicine) Hong, Kwon-Pyo (Department of Pathology, Chungbuk National University College of Medicine) Kim, So-Seul (Department of Pathology, Chungbuk National University College of Medicine) Son, Seung-Myoung (Department of Pathology, Chungbuk National University College of Medicine) Yun, Seok-Joong (Department of Urology, Chungbuk National University College of Medicine) Lee, Ho-Chang (Department of Pathology, Chungbuk National University College of Medicine) Yoon, Sang-Soon (Research Institute of Dinona Inc.) Song, Hyung-Geun (Department of Pathology, Chungbuk National University College of Medicine) |
1 | Buettner R, Huang M, Gritsko T, Karras J, Enkemann S, Mesa T, Nam S, Yu H, Jove R: Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5;823-832, 2007. DOI ScienceOn |
2 | Shi XX, Zhang B, Zang JL, Wang GY, Gao MH: CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer. Cell Mol Immunol 6;61-66, 2009. DOI ScienceOn |
3 | Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M: Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10;922-931, 2010. DOI ScienceOn |
4 | Yan J, Allendorf DJ, Li B, Yan R, Hansen R, Donev R: The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 632;159-174, 2008. |
5 | Rushmere NK, Knowlden JM, Gee JM, Harper ME, Robertson JF, Morgan BP, Nicholson RI: Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer 108;930-936, 2004. DOI ScienceOn |
6 | Jarvis GA, Li J, Hakulinen J, Brady KA, Nordling S, Dahiya R, Meri S: Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 71;1049-1055, 1997. DOI ScienceOn |
7 | Sivasankar B, Longhi MP, Gallagher KM, Betts GJ, Morgan BP, Godkin AJ, Gallimore AM: CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy? J Immunol 182;5203-5207, 2009. DOI ScienceOn |
8 | Hu W, Yu Q, Hu N, Byrd D, Amet T, Shikuma C, Shiramizu B, Halperin JA, Qin X: A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol 184; 359-368, 2010. DOI ScienceOn |
9 | Meri S, Waldmann H, Lachmann PJ: Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest 65;532-537, 1991. |
10 | Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M, Vigar MA, van der Wetering S, Morgan BP, Troost D, Baas F: The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J Neurosci 27;7663-7672, 2007. DOI ScienceOn |
11 | Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X: Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 104;550-558, 2009. DOI ScienceOn |
12 | Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F: Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement- regulatory proteins CD55 and CD59. Eur J Immunol 35;2175-2183, 2005. DOI ScienceOn |
13 | Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F: In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67;10556-10663, 2007. DOI ScienceOn |
14 | Babiker AA, Nilsson B, Ronquist G, Carlsson L, Ekdahl KN: Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate 62;105-114, 2005. DOI ScienceOn |
15 | Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G: Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62;224-232, 2005. DOI ScienceOn |
16 | Watson NF, Durrant LG, Madjd Z, Ellis IO, Scholefield JH, Spendlove I: Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunol Immunother 55;973-980, 2006. DOI ScienceOn |
17 | Zhao WP, Zhu B, Duan YZ, Chen ZT. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21;1405-1411, 2009. |
18 | Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S: Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 65;10562-10568, 2005. DOI ScienceOn |
19 | Vaughan TJ, Osbourn JK, Tempest PR: Human antibodies by design. Nat Biotechnol 16;535-539, 1998. DOI ScienceOn |
20 | Hoogenboom HR, Chames P: Natural and designer binding sites made by phage display technology. Immunol Today 21;371-378, 2000. DOI ScienceOn |
21 | Choi TH, Choi CW, Awh OD, Lim SM: Expression of the recombinant single-chain anti-B cell lymphoma antibody. J Biomed Lab Sci 9;111-121, 2003. |
22 | Choi GH, Lee DH, Min WK, Cho YJ, Kweon DH, Son DH, Park K, Seo JH: Cloning, expression, and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli. Protein Expr Purif 35;84-92, 2004. DOI ScienceOn |
23 | Cao M, Cao P, Yan H, Lu W, Ren F, Hu Y, Zhang S: Construction, purification, and characterization of anti- BAFF scFv-Fc fusion antibody expressed in CHO/dhfrcells. Appl Biochem Biotechnol 157;562-574, 2009. DOI ScienceOn |
24 | Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, Bader R, Slater S, Nilsson CA, Barone DS, Simon A, Bradley C, Thompson PA, Wahl AF, Ledbetter JA: CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15;2739-2746, 2009. DOI ScienceOn |
25 | Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM: Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56;3055-3061, 1996. |